Indonesia bans cough syrup material linked to 70 children deaths in Gambia

The BPOM reiterated that the four products linked to the deaths in Gambia are not registered in Indonesia, nor any other Maiden products.

Published On 2022-10-17 08:00 GMT   |   Update On 2022-10-17 08:00 GMT
Advertisement

Jakarta: Indonesia on Saturday banned ingredients linked to the deaths of 70 children in Gambia from cough syrups in the Southeast Asian country as it investigates acute kidney damage that has killed more than 20 children in the capital Jakarta this year.

Food and drug regulator BPOM also said it was investigating the possibility that the ingredients, diethylene glycol and ethylene glycol, had contaminated other materials that are used as solvents.
Advertisement
Gambia and India are investigating the deaths from acute kidney injury in the west-African country thought to be linked to cough syrups made by New Delhi-based Maiden Pharmaceuticals Ltd.
The World Health Organization has said it found "unacceptable" levels of the ingredients, which can be toxic, in four Maiden products.
"To provide protection to the public, BPOM has set a requirement at the time of registration that all medicinal syrup products for children and adults are not allowed to use diethylene glycol (DEG) and ethylene glycol (EG)," the regulator said in a statement.
The BPOM reiterated that the four products linked to the deaths in Gambia are not registered in Indonesia, nor any other Maiden products.
Tags:    
Article Source : Reuters

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News